Cited 1 times in
Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박성하 | - |
dc.contributor.author | 조덕규 | - |
dc.date.accessioned | 2024-03-22T05:49:37Z | - |
dc.date.available | 2024-03-22T05:49:37Z | - |
dc.date.issued | 2023-05 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198231 | - |
dc.description.abstract | We compared the efficacy and safety of third-standard-dose triple and third-standard-dose dual antihypertensive combination therapies in patients with mild to moderate hypertension. This was a phase II multicenter, randomized, double-blind, parallel-group trial. After a 4-week placebo run-in period, 245 participants were randomized to the third-dose triple combination (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg) or third-dose dual combination (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg, LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg, AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg) therapy groups and followed up for 8 weeks. The mean systolic blood pressure (BP) reduction was -18.3 ± 13.2, -13.0 ± 13.3, -16.3 ± 12.4, and -13.8 ± 13.2 mmHg in the ALC, AL, LC, and AC groups, respectively. The ALC group showed significant systolic BP reduction compared to the AL and AC groups at weeks 4 (P =.010 and P =.018, respectively) and 8 (P =.017 and P =.036, respectively). At week 4, the proportion of systolic BP responders was significantly higher in the ALC group (42.6%) than in the AL (22.0%), LC (23.3%), and AC (27.1%) groups (P =.013, P =.021, and P =.045, respectively). At week 8, the proportion of systolic and diastolic BP responders was significantly higher in the ALC group (59.7%) than in the AL (39.3%) and AC (42.4%) groups (P =.022 and P =.049, respectively) at week 8. Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension. © 2023 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley Periodicals Inc. | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Amlodipine | - |
dc.subject.MESH | Antihypertensive Agents / adverse effects | - |
dc.subject.MESH | Blood Pressure | - |
dc.subject.MESH | Chlorthalidone | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypertension* | - |
dc.subject.MESH | Hypotension* / chemically induced | - |
dc.subject.MESH | Losartan | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ki-Chul Sung | - |
dc.contributor.googleauthor | Soon Jun Hong | - |
dc.contributor.googleauthor | Moo-Yong Rhee | - |
dc.contributor.googleauthor | Myung-Ho Jeong | - |
dc.contributor.googleauthor | Dae-Hee Kim | - |
dc.contributor.googleauthor | Sang-Wook Lim | - |
dc.contributor.googleauthor | Kyungil Park | - |
dc.contributor.googleauthor | Jin Bae Lee | - |
dc.contributor.googleauthor | Seok-Yeon Kim | - |
dc.contributor.googleauthor | Jin-Man Cho | - |
dc.contributor.googleauthor | Goo-Yeong Cho | - |
dc.contributor.googleauthor | Jung-Ho Heo | - |
dc.contributor.googleauthor | Sang-Hyun Kim | - |
dc.contributor.googleauthor | Hae-Young Lee | - |
dc.contributor.googleauthor | Weon Kim | - |
dc.contributor.googleauthor | Deok-Kyu Cho | - |
dc.contributor.googleauthor | Sungha Park | - |
dc.contributor.googleauthor | Jinho Shin | - |
dc.contributor.googleauthor | Wook-Bum Pyun | - |
dc.contributor.googleauthor | Kihwan Kwon | - |
dc.contributor.googleauthor | Seung-Woon Rha | - |
dc.contributor.googleauthor | Jin-A Jung | - |
dc.identifier.doi | 10.1111/jch.14656 | - |
dc.contributor.localId | A01512 | - |
dc.contributor.localId | A03813 | - |
dc.relation.journalcode | J01320 | - |
dc.identifier.eissn | 1751-7176 | - |
dc.identifier.pmid | 37095689 | - |
dc.subject.keyword | combination therapy | - |
dc.subject.keyword | hypertension | - |
dc.subject.keyword | low-dose | - |
dc.contributor.alternativeName | Park, Sung Ha | - |
dc.contributor.affiliatedAuthor | 박성하 | - |
dc.contributor.affiliatedAuthor | 조덕규 | - |
dc.citation.volume | 25 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 429 | - |
dc.citation.endPage | 439 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL HYPERTENSION, Vol.25(5) : 429-439, 2023-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.